SLNO (Soleno Therapeutics) Future Price to Earnings

Corporate emblem and logo of Soleno (SLNO)

The forward P/E ratio for Soleno Therapeutics (SLNO) reflects valuation dynamics where the value remains at 7.20, correlating with the low predictability of current cash flows prior to commercialization. Fundamentally, the business relies on the high macro-resilience of the healthcare sector, despite its dependence on external capital. The primary potential is concentrated in the breakthrough launch of the DCCR drug for the therapy of Prader-Willi syndrome.

SLNO - Soleno Therapeutics Inc Projected Price to Earnings Ratio over the range 07/04/2022 - 05/30/2026

Analytical breakdowns for Soleno Therapeutics

- current price and projected stock value:
General company analysis:SLNO soleno.life
Brand item of Soleno Therapeutics Corp

The forward P/E reflects market earnings expectations, comparing current market capitalization with projected income to determine the degree of asset overvaluation. By analyzing the forward P/E metric of Soleno Therapeutics (SLNO), an investor assesses the risks of inflated expectations, which is critical for Soleno Therapeutics (SLNO) as revenue remains volatile until the commercial launch of drugs for the treatment of genetic pathologies.

Competitors of Soleno Therapeutics (SLNO)

Projected Price to Earnings ASND (Ascendis Pharma Inc.)|MDGL (Madrigal Corp) - Future Price to Earnings Multiple|Future Price to Earnings corcept.com CORT|RYTM - Projected Price to Earnings|Akero Corp - Forward P/E Multiple|Projected Price to Earnings Ratio Metsera Corp|MLTX (MoonLake) - Projected Price to Earnings|CRNX: Market Cap to Future Earnings Ratio|NAMS (NewAmsterdam Pharma Corp) - Forward P/E Multiple|Forward P/E Multiple Amicus Therapeutics|Forward P/E Multiple ETNB|Future Price to Earnings AGIO (Agios)|Future Price to Earnings structuretx.com GPCR|MiMedx Corp (MDXG) - Projected Price to Earnings Ratio|RZLT - Future Price to Earnings|LXRX: Future Price to Earnings|MBX Biosciences, Inc. (MBX) - Future Price to Earnings|ALT - Market Cap to Projected Earnings|Future Price to Earnings Aardvark Pharma|Sagimet Biosciences Inc (SGMT) - Market Cap to Projected Earnings|Future Price to Earnings bioagelabs.com (BIOA)|Projected Price to Earnings Biomea Fusion, Inc. BMEA|Future Price to Earnings Quince QNCX|GUTS (Fractyl Health Inc.) - Price to Expected Earnings Ratio|VTVT: Projected Price to Earnings|Forward Price to Earnings Multiple agapeatpgroup.com (ATPC)|PLUR (Pluri) - Projected Price to Earnings|Price to Future Earnings Ratio SYBX|Future Price to Earnings Lipocine Corporation|matinasbiopharma.com (MTNB) - Market Cap to Projected Earnings|Forward P/E Multiple SPRB|Projected Price to Earnings Galecto, Inc. GLTO|Future Price to Earnings Carmell Corporation CTCX|Future Price to Earnings Multiple LUMO|ONVO: Projected Price to Earnings|Future Price to Earnings Multiple RDUS (Radius Recycling Inc.)